Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective

References

• Diabetes Statistics in Canada. Diabetes Canada; 2015. http://www.diabetes.ca/how-you-can-help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada. [Last accessed 23 April 2017]
   Google Scholar
• Canadian Diabetes Association. An economic tsunami the cost of diabetes in Canada; 2009. https://www.diabetes.ca/CDA/media/documents/publications-and-newsletters/advocacy-reports/economic-tsunami-cost-of-diabetes-in-canada-english.pdf. [Last accessed 23 April 2017]
   Google Scholar
• Public Health Agency of Canada. Diabetes in Canada: Facts and figures from a public health perspective; 2011. http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/highlights-saillants-eng.php#chp1. [Last accessed 13 January 2017]
   Google Scholar
• CNIB. About diabetic retinopathy; 2017. http://www.cnib.ca/en/your-eyes/eye-conditions/eye-connect/DR/About/Pages/default.aspx. [Last accessed 13 January 2017]
   Google Scholar
• CNIB. Eye connect: diabetic retinopathy, 2017. http://www.cnib.ca/en/your-eyes/eye-conditions/eye-connect/DR/Pages/default.aspx. [Last accessed 13 January 2017]
   Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015;64:631-42
   PubMed Web of Science ®Google Scholar
• Writing Group for the DERG, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert C, Booth G, Cheng AY. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37(Suppl1):S1-S212
   Web of Science ®Google Scholar
• Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-8
   PubMed Web of Science ®Google Scholar
• Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-76
   PubMed Web of Science ®Google Scholar
• Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155-62
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317:371-8
   PubMed Web of Science ®Google Scholar
• Marcus Lind WP, Hirsch IB, Heise T, et al. Continuous glucose monitoring vs. conventional therapy for glycemic control in adults with Type 1 diabetes treated with multiple daily injections The GOLD Randomized Clinical Trial. JAMA 2017;317:1-10
   Web of Science ®Google Scholar
• Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol 2015;9:209-14
   PubMedGoogle Scholar
• Dexcom G5 Mobile Continuous Glucose Monitoring System User Guide. San Diego, CA: Dexcom, Inc.; 2016. https://dexcompdf.s3.amazonaws.com/G5-Mobile-UG-OUS-ENCA-mmol.pdf. [Last accessed 16 July 2017]
   Google Scholar
• Dexcom G4 PLATINUM Continuous Glucose Monitoring Systems User Guide. San Diego, CA: Dexcom, Inc.; 2016. https://s3-us-west-2.amazonaws.com/dexcompdf/LBL-012080+G4+PLATINUM+with+Spritz.pdf. [Last accessed 16 July 2017]
   Google Scholar
• Riemsma R, Corro Ramos I, Birnie R, et al. Integrated sensor-augmented pump therapy systems [the MiniMed(R) Paradigm Veo system and the Vibe and G4(R) PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technol Assess 2016;20:v–xxxi,1–251
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Val Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• Guidelines for the Economic Evaluation of Health Technologies. Canada; 4th Edition. 2017. https://cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition. [Last accessed 17 July 2017]
   Google Scholar
• UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Economics 2015;18:420-32
   PubMed Web of Science ®Google Scholar
• Battelino T, Liabat S, Veeze HJ, et al. Routine use of continuous glucose monitoring in 10,501 people with diabetes mellitus. Diabet Med 2015;32:1568-74
   PubMed Web of Science ®Google Scholar
• JDRF Continuous Glucose Monitoring Study Group, Bode B, Beck RW, et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009;32:2047-9
   PubMed Web of Science ®Google Scholar
• JDRF Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17-22
   PubMed Web of Science ®Google Scholar
• Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010;8:18
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Beaudet A, Clegg J, Thuressom P-O, et al. Review of utility values for economic modeling in type 2 diabetes. Val Health 2014;17:462-70
   PubMed Web of Science ®Google Scholar
• Harris SB, Yale J-F, Chiasson J-L, et al. Out-of-pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes 2007;31:25-33
   Google Scholar
• O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7
   PubMed Web of Science ®Google Scholar
• CADTH. CADTH Optimal Use report; United Kingdom, 2013
   Google Scholar
• IMS Health. Cost-Effectiveness analysis of dulaglutide 1.5mg vs. exenatide once weekly using the IMS CORE Diabetes Model in the Slovak setting; 2016. https://kategorizacia.mzsr.sk/Lieky/Download/ObjectionRequestAttachment/1176. [Last accessed 14 July 2017]
   Google Scholar
• Riddlesworth T, Price D, Cohen N, et al. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther 2017;8:947-951
   PubMed Web of Science ®Google Scholar
• International Hypoglycaemia Study G. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017;40:155-7
   PubMed Web of Science ®Google Scholar
• van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 2016;4:893-902
   PubMed Web of Science ®Google Scholar
• Marrett E, Stargardt T, Mavros P, et al. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab 2009;11:1138-44
   PubMed Web of Science ®Google Scholar
• Vexiau P, Mavros P, Krishnarajah G, et al. Hypoglycemia in patients with type 2 diabetes treated with a combination of metformin and sulfonylurea therapy in France. Diabetes Obes Metab 2008;10:16-24
   PubMed Web of Science ®Google Scholar
• Stargardt T, Gonder-Frederick L, Krobot KJ, et al. Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health and Quality of Life Outcomes 2009;7:91
   PubMed Web of Science ®Google Scholar
• Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ 2015;18:45-55
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
   PubMedGoogle Scholar
• Gilet H, Gruenberger J-B, Bader G, et al. Demonstrating the burden of hypoglycemia on patients’ quality of life in diabetes clinical trials: measurement considerations for hypoglycemia. Val Health 2012;15:1036-41
   PubMed Web of Science ®Google Scholar
• Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15
   PubMed Web of Science ®Google Scholar
• Edelman SV, Blose JS. The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes. Diabetes Educ 2014;40:269-79
   PubMed Web of Science ®Google Scholar
• Shi L, Shao H, Zhao Y, et al. Is hypoglycemia fear independently associated with health-related quality of life. Health Qual Life Outcomes 2014;12:167
   PubMed Web of Science ®Google Scholar
• FDA Press release. FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decision; 2016. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534056.htm. [Last accessed 14 July 2017]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Ontario Drug Benefit Formulary/Comparative Drug Index; 2014. Edition 42. Ministry of Health and Long-Term Care, Ontario, Canada
   Google Scholar
• Ontario Public Drug Programs - Reimbursement levels for Blood Glucose Test Strips. Ontario Ministry of Health and Long-term Care 2013. http://www.health.gov.on.ca/en/pro/programs/drugs/teststrips/bg_teststrips.aspx. [Last accessed 23 April 2017]
   Google Scholar
• Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in well-controlled adults with type 1 diabetes. Diabetes Care 2017;40:538-45
   PubMed Web of Science ®Google Scholar
• McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013;19:792-9
   PubMed Web of Science ®Google Scholar
• Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med 2013;30:767-77
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017;40:736-41
   PubMed Web of Science ®Google Scholar
• Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab 2015;41:116-25
   PubMed Web of Science ®Google Scholar
• Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703
   PubMed Web of Science ®Google Scholar
• Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocrine Pract 2010;16:244-8
   PubMed Web of Science ®Google Scholar
• Huang ES, O’Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010;33:1269-74
   PubMed Web of Science ®Google Scholar
• McQueen RB, Ellis SL, Campbell JD, et al. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Effectiveness and Resource Allocation 2011;9:13
   PubMedGoogle Scholar
• Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health 2012;15:632-8
   PubMed Web of Science ®Google Scholar
• Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014;17:561-9
   PubMed Web of Science ®Google Scholar
• Roze S, Smith-Palmer J, Valentine W, et al. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technol Ther 2016;18:75-84
   PubMed Web of Science ®Google Scholar
• Roze S, Smith-Palmer J, Valentine WJ, et al. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. J Med Econ 2016;19:236-42
   PubMed Web of Science ®Google Scholar
• Giani E, Snelgrove R, Volkening LK, et al. Continuous glucose monitoring (CGM) adherence in youth with type 1 diabetes: associations with biomedical and psychosocial variables. J Diabetes Sci Technol 2016;11:476-483
   PubMedGoogle Scholar
• Jaswal A. Canada 2020 analytical commentary No.3: valuing health in Canada. Who, how, and how much? 2013. http://canada2020.ca/wp-content/uploads/2013/06/Canada-2020-Analytical-Commentary-No-3-Valuing-Health-in-Canada-FINAL.pdf. [Last accessed 12 July 2017]
   Google Scholar